For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Aveo Pharmaceuticals, Inc.

USPTO Granted Patents = 40

EPO Patents = 11

Trademarks = 6

Forward Citations = 163

Loading Chart...

Loading Chart...

65 inventors (with patents filed for the assignee):

William M Winston, Jr (28 out of 28 patents)

Jeno Gyuris (28 out of 28 patents)

Lyne Breault (17 out of 17 patents)

4. Solly Weiler (14 out of 14 patents)

5. Ting Chen (13 out of 80 patents)

6. Jie Lin (12 out of 13 patents)

7. May Han (11 out of 11 patents)

8. Kristan Meetze (10 out of 12 patents)

9. Lorena Lerner (9 out of 9 patents)

10. S Kirk Wright (9 out of 9 patents)

11. Bijan Etemad-Gilbertson (9 out of 10 patents)

12. Christine Knuehl (9 out of 9 patents)

13. Sandra Abbott (8 out of 8 patents)

14. Sylvie Vincent (8 out of 8 patents)

15. Steve Bottega (8 out of 8 patents)

Core Competencies:

Anti-Notch3 Antibody

Anti-GDF-15 Antibodies

Chronic Kidney Disease

Refractory Cancer Treatment

Anti-ErbB3 Antibodies

Cancer Drug Discovery

Hepatocyte Growth Factor

Fibroblast Growth Factor Receptor

Tumor Response Prediction

Chimeric Cancer Models

EMT Gene Signatures

Directed Complementation

40 patents: Sort by Forward Citations

1. 12338282 - Anti-Notch3 antibody (2025-06-24),

2. 12269877 - Anti-notch3 antibodies (2025-04-08),

3. 12258391 - Anti-GDF-15 antibodies (2025-03-25),

4. 11897948 - Treatment of chronic kidney disease and other renal dysfunction using a GDF15 modulator (2024-02-13),

5. 11725047 - Anti-GDF-15 antibodies (2023-08-15),

6. 11680108 - Anti-ErbB3 antibodies (2023-06-20),

7. 11504365 - Use of tivozanib to treat subjects with refractory cancer (2022-11-22),

8. 11142573 - Anti-Notch3 antibody (2021-10-12),

9. 10745476 - Anti-NOTCH3 antibodies (2020-08-18),

10. 10597444 - Anti-GDF15 antibodies (2020-03-24),

11. 10494441 - Anti-ERBB3 antibodies (2019-12-03),

12. 9896730 - Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment (2018-02-20),

13. 9879083 - Anti-Notch3 antibodies (2018-01-30),

14. 9828635 - Predicting tumor response to anti-ERBB3 antibodies (2017-11-28),

15. 9725505 - Methods of treatment using anti-GDF15 antibodies (2017-08-08),

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing targeted cancer therapeutics. They focus on advancing their lead product candidate, tivozanib, for the treatment of various forms of cancer. AVEO is committed to improving the lives of patients and providing effective treatment options for oncology challenges.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

40 Patents

#60 in Boston, MA

#484 in Massachusetts

#8,342 in US

#16,562 in the World

Boston, MA, United States of America

Aveo Pharmaceuticals, Inc.

Forward Citations = 163

65 inventors:

William M Winston, Jr (28 out of 28 patents)

Jeno Gyuris (28 out of 28 patents)

Lyne Breault (17 out of 17 patents)

4. Solly Weiler (14 out of 14 patents)

5. Ting Chen (13 out of 80 patents)

Please report any incorrect information to support@idiyas.com

Loading…